Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bio-Rad Laboratories (BIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,764,777
  • Shares Outstanding, K 29,799
  • Annual Sales, $ 2,289 M
  • Annual Income, $ 365,610 K
  • 60-Month Beta 1.27
  • Price/Sales 3.80
  • Price/Cash Flow 49.22
  • Price/Book 2.16

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 1.12
  • Number of Estimates 2
  • High Estimate 1.26
  • Low Estimate 0.97
  • Prior Year 1.17
  • Growth Rate Est. (year over year) -4.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
287.89 +1.95%
on 04/17/19
311.73 -5.85%
on 04/03/19
-12.10 (-3.96%)
since 03/22/19
3-Month
233.18 +25.86%
on 01/23/19
323.95 -9.40%
on 03/01/19
+57.97 (+24.61%)
since 01/22/19
52-Week
220.05 +33.37%
on 12/26/18
345.15 -14.97%
on 08/08/18
+32.81 (+12.59%)
since 04/20/18

Most Recent Stories

More News
Bio-Rad Appoints Andrew Last as Executive Vice President and Chief Operating Officer

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the appointment of Dr. Andrew Last as Executive...

BIO : 293.49 (-0.22%)
Abbott (ABT) Q1 Earnings Beat Estimates, Organic Sales Solid

Abbott (ABT) reports strong and consistent EPD and Medical Devices performance organically in Q1.

ABT : 74.51 (+0.80%)
LMAT : 27.40 (+0.59%)
BIO : 293.49 (-0.22%)
DXCM : 116.61 (+2.03%)
Bio-Rad to Report First-Quarter 2019 Financial Results

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the first quarter 2019 on Wednesday,...

BIO : 293.49 (-0.22%)
Weekly Jobless Claims Lowest in Nearly 50 Years: 5 Top Picks

The U.S. labor market is the major driver of the bull run, which is more than a decade old.

DIN : 88.19 (-0.45%)
BIO : 293.49 (-0.22%)
PWR : 39.82 (-0.47%)
NSP : 122.13 (+0.88%)
BSTC : 63.00 (-0.30%)
Bio-Rad's (BIO) IH-500 System Secures 510(K) From the FDA

The regulatory go-ahead is in line with Bio-Rad's (BIO) strategy of strengthening in the transfusion medicine market of the United States.

SYK : 182.16 (+1.05%)
AMED : 114.00 (-2.75%)
PEN : 129.91 (+0.73%)
BIO : 293.49 (-0.22%)
Bio-Rad Receives U.S. FDA Clearance for the IH-500, Expanding Its Offering for the Blood Testing Market

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has received 510(k) clearance from the...

BIO : 293.49 (-0.22%)
Bio-Rad's Latest FDA Nod to Boost Clinical Diagnostics Arm

The recent development will help Bio-Rad (BIO) rake in increased top-line contributions from the Clinical Diagnostics business.

AMED : 114.00 (-2.75%)
ILMN : 319.09 (+0.02%)
PEN : 129.91 (+0.73%)
BIO : 293.49 (-0.22%)
Bio-Rad Labs-A Has Returned 28.9% Since SmarTrend Recommendation (BIO)

SmarTrend identified an Uptrend for Bio-Rad Labs-A (NYSE:BIO) on January 11th, 2019 at $240.10. In approximately 3 months, Bio-Rad Labs-A has returned 28.91% as of today's recent price of $309.52.

BIO : 293.49 (-0.22%)
Bio-Rad Names Ilan Daskal Executive Vice President and Chief Financial Officer

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the appointment of Ilan Daskal as Executive Vice...

BIO : 293.49 (-0.22%)
Bio-Rad Announces Innovative Test to Aid in the Diagnosis of Lyme Disease with the FDA Clearance of the BioPlex 2200 Lyme Total Assay

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has received U.S. Food and Drug Administration...

BIO : 293.49 (-0.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade BIO with:

Business Summary

Bio-Rad Laboratories, Inc., together with its subsidiaries, engages in the manufacture and supply of products and systems for the life science research, healthcare, analytical chemistry, and other markets worldwide. The company's products are used to separate complex chemical and biological materials,...

See More

Key Turning Points

2nd Resistance Point 299.42
1st Resistance Point 296.46
Last Price 293.49
1st Support Level 291.50
2nd Support Level 289.50

See More

52-Week High 345.15
Fibonacci 61.8% 297.36
Last Price 293.49
Fibonacci 50% 282.60
Fibonacci 38.2% 267.84
52-Week Low 220.05

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar